Stockscreener 앱 받기
2.10
4.11%
-0.09
시간 외 거래:
2.17
0.07
+3.33%
전일 마감가:
$2.19
열려 있는:
$2.18
하루 거래량:
663.63K
Relative Volume:
0.51
시가총액:
$72.54M
수익:
$300.00K
순이익/손실:
$-24.74M
주가수익비율:
-2.0875
EPS:
-1.006
순현금흐름:
$-19.19M
1주 성능:
-6.25%
1개월 성능:
-14.29%
6개월 성능:
+147.20%
1년 성능:
+90.91%
1일 변동 폭
$2.08
$2.2371
1주일 범위
$2.08
$2.26
52주 변동 폭
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
명칭
iBio Inc
전화
302-355-0650
주소
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.10 | 75.65M | 300.00K | -24.74M | -19.19M | -1.006 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Oppenheimer | Outperform |
| 2025-10-17 | 개시 | Leerink Partners | Outperform |
| 2024-05-28 | 개시 | Chardan Capital Markets | Buy |
| 2021-11-29 | 개시 | JMP Securities | Mkt Outperform |
| 2021-01-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 개시 | Alliance Global Partners | Buy |
모두보기
iBio Inc 주식(IBIO)의 최신 뉴스
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - ADVFN
Top iBio (IBIO) Competitors 2026 - MarketBeat
iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
Ibio (IBIO) Receives a Buy from Chardan Capital - The Globe and Mail
IBIO: Chardan Capital Maintains 'Buy' Rating with $5.00 Price Ta - GuruFocus
Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity - BioWorld News
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - Sahm
iBio receives approval to start phase 1 trial of IBIO-600 By Investing.com - Investing.com Australia
iBio Receives Regulatory Clearance to Begin Phase 1 Trial of IBIO-600, a Long-Acting Anti-Myostatin Antibody for Obesity, in Australia 1 - Minichart
iBio, Inc. (IBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
iBio Advances to Clinical Stage With IBIO-600 Trial - TipRanks
iBio, Inc. (IBIO) stock price, news, quote and history - Yahoo Finance UK
IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia - Stocktwits
Regulators clear iBio (NASDAQ: IBIO) to launch first-in-human IBIO-600 trial - Stock Titan
iBio receives approval to start phase 1 trial of IBIO-600 - Investing.com
Street Watch: Is iBio Inc a speculative investment2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Aug Selloffs: Will iBio Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
FRA:0JV0 PB Ratio: 1.01 — 33% Below Median - GuruFocus
IBIO Should I Buy - Intellectia AI
iBio Inc. (0JV0.SG) cash flow - Yahoo Finance UK
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
Can iBio Inc stock double in the next yearQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Insider List - GuruFocus
Insider Buying: Marc Banjak Acquires Additional Shares of iBio I - GuruFocus
iBio chief legal officer Banjak buys shares worth $23,055 By Investing.com - Investing.com South Africa
iBio chief legal officer Banjak buys shares worth $23,055 - Investing.com
Insider Banjak Marc buys 13,934 iBio (IBIO) shares in open market - Stock Titan
Leerink reiterates Outperform on iBio stock amid competitor data By Investing.com - Investing.com South Africa
Leerink reiterates Outperform on iBio stock amid competitor data - Investing.com
IBIO PB Ratio: 0.91 — 41% Below Median - GuruFocus
IBIO Plummets Nearly 21%: A Biotech Ticker Stumbles in the Face of Technical Breakdown - Bitget
These stocks that are showing activity before the opening bell on Thursday. - ChartMill
Panic Selling: Is iBio Inc impacted by rising ratesWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Insider Buying: Felipe Duran Acquires Shares of iBio Inc (IBIO) - GuruFocus
iBio CFO Duran acquired $50k in shares on March 19 - Investing.com India
INB.bio Launches Rebuilt Ai-Powered Affiliate Crm Platform - MarketScreener
Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock - MarketBeat
iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares - MarketBeat
iBio director Brenner buys $24918 in company stock By Investing.com - Investing.com Australia
iBio director Brenner buys $24918 in company stock - investing.com
iBio CFO Duran acquired $50k in shares on March 19 By Investing.com - Investing.com Australia
IBIO | iBio, Inc. Common Stock Insider Trading - Quiver Quantitative
iBio Inc (IBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):